Trastuzumab cardiotoxiciy: the age-old balance of risk and benefit
Mené sur 2 500 patientes atteintes d'un cancer du sein HER2+ de stade précoce, cet essai randomisé analyse les cardiotoxicités d'un traitement adjuvant par trastuzumab, selon la durée du traitement (6 ou 12 mois)
The cardiac sequelae of trastuzumab administration has been the subject of considerable concern dating back to the original report noting a 27% incidence of ejection fraction declines and 19% of clinical heart failure (Slamon et al, 2001). Although this trial continues to be cited, these high incidences have never been subsequently encountered.
British Journal of Cancer , éditorial, 2015